摘要
目的探讨乳腺癌特异基因(BCSG1)在"三阴"性乳腺癌新辅助化疗疗效评估中的价值。方法采用免疫组化S-P法和荧光定量PCR方法检测32例"三阴"性乳腺癌患者新辅助化疗(CEF方案)前后乳腺癌组织BCSG1的表达,比较化疗前后肿瘤体积的变化情况,分析新辅助化疗前后BCSG1蛋白表达与肿瘤形态学变化的关系。结果23例乳腺癌患者新辅助化疗后肿瘤体积均有明显缩小,病灶缓解率(CR+PR)为84.4%;新辅助化疗后BCSG1 mRNA表达水平亦明显低于化疗前(P<0.05),BCSG1蛋白高表达率低于新辅助化疗前(P<0.01)。结论BCSG1分子和蛋白水平在"三阴"性乳腺癌新辅助化疗后均明显降低,与新辅助化疗后疗效呈负相关(r=-0.584,P<0.01),提示BCSG1可作为"三阴"乳腺癌新辅助化疗疗效的预测因子。
Objective To study the value of Breast cancer-specific gene 1 （BCSG1） on evaluating the curative effect of neoadjuvant chemotherapy （NAC） for triple-negative breast cancer. Methods The expression of BCSG1 in cancer tissue was assayed by immunohistochemistry and RTPCR in 32 cases of triple-negative breast cancer patients before and after receiving NAC of CEF （cyclophosphamide,epirubicin and fluorouracil） regimen. The therapeutic response of NAC was evaluated by morphological and pathological observation. The relationship between expression of BCSG1 and morphological response to NAC was analyzed before and after meoadjuvant chemotherapy. Results Among the studied cases, the diameter of tumor was significantly decreased and the focal remission rate （CR＋PR） was 84.4%. The expression of BCSG1 mRNA and the high expression rate of BCSG1 （P〈0.01） were decreased significantly after receiving NAC than that before NAC（P〈0.05 and P〈0.01 respectively）. Conclusions After NAC, the expression of BCSG1 mRNA and protein was decreased significantly, which had negative relation to the therapeutic effect of NAC. BCSG1 might be a prognosticate factor to evaluate the effect of NAC in triple-negative breast cancer patients.
出处
《岭南现代临床外科》
2009年第3期167-169,175,共4页
Lingnan Modern Clinics in Surgery
基金
广东省医学科学技术研究基金(No:A2008605)
深圳市科技计划项目研究基金(No:200802030)
关键词
“三阴”乳腺癌
乳腺癌特异基因
新辅助化疗
Triple-negative breast cancer
Breast cancer-specific gene
Neoadjuvant chemotherapy
